2025-04-15 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Review

**0. Key Figures & Initial Analysis:**

ISRG, Intuitive Surgical Inc., is a leading medical device company specializing in robotic-assisted surgery systems.  The company shows significantly higher cumulative returns than the S&P 500 (VOO) over the analyzed period.

**1. Performance vs. S&P 500 (VOO):**

* **ISRG Cumulative Return:** 112.33%
* **VOO Cumulative Return:** 66.69%
* **Return Difference:** 45.6%  (This signifies that ISRG outperformed VOO by 45.6 percentage points over the period.)
* **Relative Outperformance:** 40.8% (Based on the provided historical range of -6.7% to 121.5%, the current outperformance sits at the 40.8th percentile.)

The table below shows the Compound Annual Growth Rate (CAGR), Maximum Drawdown (MDD), Alpha, Beta, and market capitalization over various periods:

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 68.0% | 56.5% | 38.0% | 0.0 | 43.6 |
| 2016-2018  | 77.0% | 63.4% | 60.0% | 0.0 | 57.2 |
| 2017-2019  | 81.0% | 63.4% | 52.0% | 0.3 | 70.6 |
| 2018-2020  | 47.0% | 63.4% | 22.0% | 0.2 | 97.7 |
| 2019-2021  | 91.0% | 63.0% | 37.0% | 0.3 | 128.7 |
| 2020-2022  | -3.0% | 69.9% | -9.0% | 0.3 | 95.1 |
| 2021-2023  | -5.0% | 72.9% | -22.0% | 1.0 | 120.9 |
| 2022-2024  | 26.0% | 72.9% | 9.0% | 1.0 | 187.0 |
| 2023-2025  | 33.0% | 72.9% | 19.0% | 0.6 | 175.6 |


Consistent high CAGR and relatively low MDD indicate strong historical performance.  Alpha values suggest periods of outperformance relative to the market (beta).  Note that the Alpha and Beta values seem inconsistent with the provided data. Further investigation is required to validate this information.

**2. Recent Price Movement:**

* **Closing Price:** $490.13
* **5-Day Moving Average:** $490.77
* **20-Day Moving Average:** $492.99
* **60-Day Moving Average:** $543.01

The price is below all three moving averages, suggesting a short-term bearish trend.  The recent price drop of -$0.70  (from $493.60)  indicates a minor downward correction.

**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4585 (High Risk)
* **RSI:** 43.34 (Approaching oversold territory, but not decisively so.)
* **PPO:** 0.5658 (Positive, suggesting bullish momentum, although this should be interpreted in conjunction with other indicators.)
* **20-Day Relative Divergence Change:** -11.7% (Short-term bearish divergence.)
* **Expected Return:** 54.5% (This is a high expected return, exceeding the S&P 500 significantly over a 2+ year horizon.  The validity of this figure needs further scrutiny, given the inherent uncertainties in long-term forecasting.)

The price drop, coupled with the high MRI and negative relative divergence, suggests caution.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-10-18 | $1.59  | $2.04 B     |
| 2024-07-19 | $1.48  | $2.01 B     |
| 2024-04-19 | $1.54  | $1.89 B     |
| 2023-10-20 | $1.18  | $1.74 B     |
| 2024-10-18 | $1.18  | $1.74 B     |

There's a duplicate entry in the table.  Assuming it's an error and focusing on the unique entries shows relatively stable revenue with some minor fluctuations in EPS.  A more thorough analysis would require additional financial information and contextual data.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.41B | 68.04% |
| 2024-09-30 | $2.04B | 67.41% |
| 2024-06-30 | $2.01B | 68.30% |
| 2024-03-31 | $1.89B | 65.87% |
| 2023-12-31 | $1.93B | 66.24% |

Revenue shows a strong upward trend, with high and stable profit margins.


**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $16.43B | 4.17% |
| 2024-09-30 | $15.58B | 3.63% |
| 2024-06-30 | $14.71B | 3.58% |
| 2024-03-31 | $13.96B | 3.90% |
| 2023-12-31 | $13.31B | 4.56% |

Equity is increasing, indicating healthy growth.  ROE is relatively stable, though showing some minor fluctuations.

**6. Overall Analysis:**

ISRG has demonstrated strong historical performance, significantly outperforming the S&P 500.  However, recent price action suggests a short-term bearish trend. While financial statements indicate strong revenue growth and high profitability, several discrepancies in the provided data (e.g., duplicate earnings data, inconsistent alpha/beta values) require further investigation and clarification before making informed investment decisions. The high expected return should be viewed with skepticism, as it's based on projections that are subject to significant market risks and unforeseen circumstances.  A more comprehensive analysis including consideration of competitive landscape, technological advancements, and regulatory factors is necessary for a thorough evaluation.  Before making any investment decisions, consultation with a qualified financial advisor is highly recommended.
